Research
Intelligence Vault
Market intelligence reports built from live executive search mandates and operator-level data across radiopharma, CDMO, ADC, and cell and gene therapy.
Need bespoke market intelligence? Commission a briefing.
The Isotope Production Map, Q3 2026: Executive Brief
How many of the isotopes you depend on come out of one building, with no named backup? The free brief carries a supply verdict for every radionuclide we profiled, the coverage country by country, and one complete producer table. The other 74 tables are in the paid edition.
Going deeper? The Isotope Production Map, Q3 2026 edition - every producer, route and capacity tier in medical isotope supply. 79 radionuclides, 94 countries, 272 organisations, 244 pages. From $1,495. Read more →
The Manufacturing Veto: Why Radiopharma Approvals Fail at the Facility
The FDA refused ITM-11 without asking a single question about the clinical data. Every objection sat in manufacturing, at a factory ITM does not own. Read against 291 rejection letters, and the seven seats that hold the veto.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Radiopharmaceutical Blueprint 2026: 889 Organizations, Eight Layers, and the Year the Sector Was Repriced
Last year we named about 130 companies to make an argument. This year we counted them: 889, across eight layers and 81 countries. It lands on the afternoon two deals agreed to take both ends of the chain off the public market.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Shortage Can End Before the System Scales: An Ac-225 Systems Analysis 2026-2035
Every alpha capacity plan assumes actinium-225 is the thing to fix. Model the whole chain instead and something uncomfortable falls out: the isotope can stop being scarce while the system stays just as hard to run.
Want to run the scenarios yourself? The Ac-225 Bottleneck Explorer - the interactive version of this analysis, free inside the article. Pick a scenario and a year, and it names the layer that binds. Open the model →
The Financial Half-Life: The Reimbursement Cliff in Radiopharma
Everyone is watching the isotopes. The money went somewhere else. The surplus in radioligand therapy has quietly decoupled from both the science and the clinical work, and a second clock is now running on reimbursement.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
Peak Actinium: The Ac-225 Scarcity Cliff - Free Extract
Close to $8bn of alpha M&A rests on one belief: that actinium-225 stays scarce. This free extract argues the belief is correct today, about to stop being correct, and dates the turn.
Going deeper? Peak Actinium: The Complete Analysis - the complete supply, demand, purity and exposure read on when the actinium-225 scarcity trade breaks. From $1,495. Read more →
The Capital Map: Money Is Everywhere. The Two Things It's Chasing Aren't.
Around $2.1 trillion of dealmaking firepower against a patent cliff exposing $300 billion by 2030. So capital is not the constraint. What money cannot buy quickly is what this maps.
Investing in a complex modality asset? Try the Diligence Gap tool Open the tool →
The Borrowed Bench: Who Actually Runs Quality Across Four Advanced Modalities
82 per cent of recent radiopharma quality hires came from outside the field. 16.4 years in pharmaceutical quality, 3.2 in radiopharma. The headcount gap is the obvious story. The experience gap is the one that meets an inspector.
The 120-Day Line: How the NRC's 2026 Byproduct Rule Rewired the Economics of Nuclear Medicine
The NRC's 2026 byproduct rule is landing across the sector as relief. It is, but only for the part of nuclear medicine that already worked. A single 21.8-year contaminant now sorts actinium producers by how they make it.
The Execution Gap: A Global Macro Map of Where Biopharma Is Actually Heading, 2026-2029
Biopharma is priced on biology and constrained by physics. Four collisions, a bottleneck map by modality, and nine falsifiable predictions to 2029, all converging on one scarce profile.
The ADC Supply Squeeze - Free Extract
Around 2,875 net-new specialist ADC roles announced, almost all dated 2029 and 2030, against a US life-sciences pool already near full employment. One exhibit from the full report, free.
Going deeper? The ADC Supply Squeeze - the supply-side read of the antibody-drug conjugate sector across capacity, chokepoints, and the specialist talent gap behind the announced build-out. From $1,495. Read more →
The State of ADCs 2026 - Early Access Extract
Eighteen pages pulled from a sixty-thousand-word report: the inverted attrition curve, the Bag-Holder Architecture, and why chemistry now carries a valuation premium.
Going deeper? The State of ADCs 2026 - the structural read of the antibody-drug conjugate sector across chemistry, manufacturing oligopoly, capital structure, and clinical strategy. From $1,495. Read more →
The Radiopharma Capacity Crunch: Clinical Pipeline vs Manufacturing Reality
343 clinical programmes, 38 isotopes and 92 CDMOs, overlaid on one map to show where demand outruns supply and which bottleneck breaks first.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Capacity Mirage: The Five Hidden Forces Repricing Contract Manufacturing in 2026
Five forces are quietly repricing contract manufacturing. Investors, operators and PE sponsors are still modelling the sector as though none of them exists.
Going deeper? CDMO Weaponised Capacity 2026 - the full operating-reality assessment of the post-BIOSECURE CDMO sector. From $1,495. Read more →
The Alpha Execution Doctrine: Why Targeted Alpha Therapy Is Not a Molecule Problem
Alpha therapy programmes rarely fail on the molecule. They fracture one layer down, in the infrastructure, and they do it in a pattern you can diagnose before you commit.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Grid Is the IP: How Radiopharma's Value Chain Inversion Will Reshape Who Wins Over the Next 36 Months
Value in radiopharma is inverting: away from the molecule, towards the grid that delivers it. Who that makes, who it stalls, and who quietly gets starved out.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Solvent Trap: 2026 – Why The West Cannot Physically Manufacture The Oral GLP-1 Wave
The oral GLP-1 wave needs manufacturing capacity the West does not physically have. Not a cost problem, not a will problem. A solvent problem.
Going deeper? CDMO Weaponised Capacity 2026 - the full operating-reality assessment of the post-BIOSECURE CDMO sector. From $1,495. Read more →
The Great CDMO Constriction – Why time, not capacity, is now breaking the CDMO system
Everyone is building capacity. Capacity stopped being the constraint. Time is now, and this maps where the constriction bites hardest.
Going deeper? CDMO Weaponised Capacity 2026 - the full operating-reality assessment of the post-BIOSECURE CDMO sector. From $1,495. Read more →
Radiopharma Disconnect: 2026 – The “House of Cards” behind the Alpha Pivot
Capital is pouring into the alpha pivot. The infrastructure underneath it is not keeping pace. Where the structure is thinner than the story.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
ADCs: The Chemical War Within - A Systems-Level Industry Analysis (2026)
Conjugation, containment, and the people who can run both. A systems-level read of ADC manufacturing and the bottleneck nobody budgets for.
Going deeper? The State of ADCs 2026 - the structural read of the antibody-drug conjugate sector across chemistry, manufacturing oligopoly, capital structure, and clinical strategy. From $1,495. Read more →
The Great Convergence: Cross-Modality Compensation Guide 2026
What advanced-modality leadership actually costs in 2026, set side by side across radiopharma, CDMO, cell and gene, ADC and biotech.
The CDMO Reckoning: 2026 - Why Capacity No Longer Wins
Capacity used to decide who won in contract manufacturing. It no longer does. Where the value is migrating instead.
Going deeper? CDMO Weaponised Capacity 2026 - the full operating-reality assessment of the post-BIOSECURE CDMO sector. From $1,495. Read more →
Radiopharma Compensation Benchmark 2026 (US)
What US radiopharma leadership actually pays, VP to C-suite, by function and organisation type. The numbers, not the ranges everyone quotes.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Great Convergence: 2026 - From Science Projects to Scale
Advanced modalities are leaving the science-project phase. The talent and infrastructure gaps that decide which of them reaches scale.
The Talent Migration Report - Advanced Modality Talent Forecast 2025 - 2027
Where advanced-modality talent is moving through 2027, who is losing it, and which functions are about to get expensive.
The Regulatory Approval Blueprint: Building Programs Designed to Survive FDA Review
Approval programmes fail in patterns, and the patterns are visible years ahead. How to build one designed to survive review rather than hope for it.
The Hybrid Delusion: RLT, ADC & CDMO Reality
The combined RLT and ADC facility is a compelling story. Operationally it mostly is not real. Where the narrative and the plant diverge.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Hidden Architecture of Radiopharma: Capital, Capability & Collapse
Capital and capability in radiopharma are diverging. The dependencies that creates are structural, largely invisible, and where the sector is most likely to break.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
Anatomy of a Failure - Lessons from 89 FDA CRLs that Resulted in Failure
89 Complete Response Letters that ended the programme rather than delayed it. Where approvals actually collapse, and how early the signal shows.
Radiopharma’s 4 Critical Questions: A Pre-TRP Briefing
Four questions the sector is walking into the TRP conference without a good answer to. A short pre-read for anyone attending.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The Alpha Radiopharma Launch Readiness Blueprint: Execution Risks in the $40B Modality
A $40B modality, and most launch plans inside it are carrying execution risk nobody has priced. A readiness blueprint for operators and investors.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
The $400M CMC Playbook: De-Risking Antibody Programs Before IND
$400M of exposure sits in the CMC decisions taken before IND, when they are cheapest to change and easiest to ignore.
Going deeper? The State of ADCs 2026 - the structural read of the antibody-drug conjugate sector across chemistry, manufacturing oligopoly, capital structure, and clinical strategy. From $1,495. Read more →
The Radiopharmaceutical Blueprint: Navigating the Ecosystem from Isotope to Infusion
The original Blueprint: how the radiopharmaceutical ecosystem fits together, isotope to infusion. Superseded by the 2026 edition, which counts 889 companies rather than illustrating with 130.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
Manufacturability by Design: Strategic Insights for Bispecific Antibodies
Bispecifics get designed for the clinic, then handed to a plant that cannot make them. Where manufacturability should have entered the design, and what it costs when it does not.
Going deeper? The State of ADCs 2026 - the structural read of the antibody-drug conjugate sector across chemistry, manufacturing oligopoly, capital structure, and clinical strategy. From $1,495. Read more →
Radiopharma CDMO & Supply Chain Report 2025
Who can actually make radiopharmaceuticals at scale, what they are genuinely capable of, and where the partnership market is tightening.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
Clinical Development in Radiopharma 2025 Landscape
The radiopharma pipeline as it actually stands: what is in it, how the trials are designed, and where the regulatory path narrows.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
Radiopharma Talent Brief 2025 Outlook
Where the qualified radiopharma people actually are, what they cost, and who you are competing with to get them.
Going deeper? The State of Radiopharmaceuticals 2026 - the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495. Read more →
CGT CDMO Market Outlook Q3 2025
Cell and gene manufacturing capacity has stopped being scarce. That moves the leverage, and the consolidation signals are already showing.
Going deeper? CDMO Weaponised Capacity 2026 - the full operating-reality assessment of the post-BIOSECURE CDMO sector. From $1,495. Read more →
FDA Rejection Analysis Lessons from 202 CRLs
202 Complete Response Letters, read as a dataset rather than as news. The rejection patterns repeat, and most of them were avoidable.